
Dr. Lancashire contributed to the everycure-org/matrix repository by developing features that enhanced data integrity and model evaluation in a machine learning context. Over three months, he implemented a DrugCVSplit cross-validation strategy and a leakage-free negative sampling generator, both designed to prevent data leakage between training and test sets. His work involved refactoring disease splitting logic, updating YAML-based configuration management, and adding comprehensive unit tests to validate new behaviors. Using Python and YAML, Dr. Lancashire focused on robust workflow design and reproducibility, delivering solutions that improved onboarding, access control, and the reliability of drug prediction models in production environments.

July 2025 monthly summary for everycure-org/matrix: Delivered leakage-free negative sampling for model training and refactored disease splitting to improve data integrity and evaluation reproducibility. This work eliminates data leakage between train and test sets, strengthening model evaluation and production data reliability. Key changes include the new DiseaseSplitDrugDiseasePairGenerator, refactored DiseaseAreaSplit, updated disease-splitting configuration parameters, a helper for sampling random pairs, and comprehensive tests validating the generator's behavior.
July 2025 monthly summary for everycure-org/matrix: Delivered leakage-free negative sampling for model training and refactored disease splitting to improve data integrity and evaluation reproducibility. This work eliminates data leakage between train and test sets, strengthening model evaluation and production data reliability. Key changes include the new DiseaseSplitDrugDiseasePairGenerator, refactored DiseaseAreaSplit, updated disease-splitting configuration parameters, a helper for sampling random pairs, and comprehensive tests validating the generator's behavior.
May 2025 – everycure-org/matrix: Implemented DrugCVSplit Cross-Validation Strategy to ensure distinct drug representation between training and testing sets, boosting model generalization and reducing data leakage. Added unit tests validating the new cross-validation behavior and API compliance, wired to commit 5766b9396bc275aba6478a02bb7473a51a1ef832. No major bugs fixed this month; focused on delivering a robust evaluation feature and improving data integrity. Technologies demonstrated include Python, ML workflow design, unit testing, and cross-validation API usage. Business value: more reliable model evaluation, reduced data leakage risk, and higher confidence in production drug predictions.
May 2025 – everycure-org/matrix: Implemented DrugCVSplit Cross-Validation Strategy to ensure distinct drug representation between training and testing sets, boosting model generalization and reducing data leakage. Added unit tests validating the new cross-validation behavior and API compliance, wired to commit 5766b9396bc275aba6478a02bb7473a51a1ef832. No major bugs fixed this month; focused on delivering a robust evaluation feature and improving data integrity. Technologies demonstrated include Python, ML workflow design, unit testing, and cross-validation API usage. Business value: more reliable model evaluation, reduced data leakage risk, and higher confidence in production drug predictions.
February 2025 monthly summary for everycure-org/matrix: Focused on enabling onboarding and access control by adding a new workbench user. Updated YAML-based workbench user list to include user 'lee', improving visibility and access for Lee within the workbench environment. All changes are tracked in version control with clear traceability.
February 2025 monthly summary for everycure-org/matrix: Focused on enabling onboarding and access control by adding a new workbench user. Updated YAML-based workbench user list to include user 'lee', improving visibility and access for Lee within the workbench environment. All changes are tracked in version control with clear traceability.
Overview of all repositories you've contributed to across your timeline